US stock index futures rise sharply following Gilead Sciences’ statement on remdesivir

The National Institute of Allergy and Infectious Diseases’ (NIAID) trial of the antiviral remdesivir for the treatment of COVID-19 met its primary endpoint, Gilead Sciences Inc. said in a statement on Wednesday. The company also published its results from the Phase-3 trial with key takeaways found below.

Tonight, risk-on with the expectation of economic recovery from the new Corona.
,Crude oil stock prices are both skyrocketing.

Continue to buy NZDCHF.


Currently, the power balance in 15 minutes is

CAD > EUR > NZD > AUD > USD > CHF > JPY > GBP

Leave a Reply

%d bloggers like this: